Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Genmab A/S - American Depositary Shares (NQ:GMAB)

28.08 -0.16 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria
Discover GMAB, a biotech stock matching Peter Lynch's GARP strategy. It offers strong earnings growth, a low PEG ratio, and excellent financial health for long-term investors. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): A High-Value Biotech Play with Strong Fundamentals
Genmab (GMAB) is a high-value biotech stock with a low P/E ratio, strong financial health, and robust profitability, making it a standout undervalued opportunity. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): An Affordable Growth Candidate in Biotechnology
Discover GENMAB A/S (GMAB), an affordable growth stock with strong revenue expansion, solid profitability, and a reasonable valuation in the biotech sector. 
Via Chartmill
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
From Genmab A/S
Via Business Wire
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
From Genmab
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Biotech Stock With Strong Growth and Reasonable Valuation
GENMAB A/S (NASDAQ:GMAB) is a biotech stock with strong earnings growth, high profitability, and a reasonable valuation, making it a candidate for long-term investors following Peter Lynch's strategy. 
Via Chartmill
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
From Genmab
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Candidate for GARP Investors
GENMAB A/S (NASDAQ:GMAB) offers strong earnings growth, high profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy. 
Via Chartmill
Why Genmab Stock Smashed It on Monday
Via The Motley Fool
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Growth Stock Showing Technical Breakout Potential
GENMAB A/S (NASDAQ:GMAB) is a strong growth stock with solid fundamentals and a promising technical breakout pattern, offering potential for investors seeking growth opportunities. 
Via Chartmill
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors
GENMAB A/S (NASDAQ:GMAB) offers strong growth, solid profitability, and attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for GARP Investors
GENMAB A/S (NASDAQ:GMAB) offers strong growth, profitability, and a reasonable valuation, making it a standout pick for GARP investors following Peter Lynch’s strategy. 
Via Chartmill
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals.
GENMAB A/S -SP ADR is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:GMAB showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): a strong growth stock preparing for the next leg up?.
Based on a technical and fundamental analysis of NASDAQ:GMAB we can say: GENMAB A/S -SP ADR (NASDAQ:GMAB), a strong growth stock, setting up for a breakout. 
Via Chartmill
Why Peter Lynch may take an interest in GENMAB A/S -SP ADR (NASDAQ:GMAB)
Peter Lynch, one of the most successful investors of all time, focused on growth stocks with strong fundamentals and a business model that’s easy to understand. Let’s analyze whether GENMAB A/S -SP ADR... 
Via Chartmill
Despite its growth, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains within the realm of affordability.
GENMAB A/S -SP ADR was identified as a growth stock that isn't overvalued. NASDAQ:GMAB is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize... 
Via Stocktwits
Topics Stocks
What Analysts Are Saying About Genmab Stock
 
Via Benzinga
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy?
Peter Lynch was known for finding hidden gems in the market before they became mainstream. Is GENMAB A/S -SP ADR (NASDAQ:GMAB) one of those under-the-radar stocks that fits his legendary strategy? 
Via Chartmill
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy. 
Via Benzinga
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
From Genmab A/S
Via Business Wire
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
From Genmab
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.